Artiva Biotherapeutics, Inc.

ARTV

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001817241


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $130.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs not computable: fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Apr 30, 2026 193 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$4.15 2026-11-06; market equity $202.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured and stored frozen and ready to ship to a patient's treatment location, making them what we believe to be "off-the-shelf.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 65.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(4.2%)	(6.6%)	65.0	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 42.2					
Twelve-month failure probability	0.13%	0.08%	59.7	249	2026-06-30
Altman Z double-prime	(2.34)	(0.37)	46.8	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	8.61x	2.94x	20.2	828	2025-12-31
Growth and financing, sleeve percentile 28.1					
Revenue growth, three-year compound	not computable	10.0%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	37.1%			
a prior annual working-capital observation is required					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 2					
Net share issuance, one year	1.5%	2.5%	28.1	630	2026-02-27

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	70.7%	(2.1%)	83
Distance from 52-week high	(69.0%)	(30.4%)	14
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(39.1%)	(1.0%)	17
Book value to price	1.71	0.29	94
Sales to price	0.00	0.30	0
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	0.37	(0.19)	83

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$301.5M
Operating cash flow, four quarters	-$75.2M
Months of runway	48.1
Days since last periodic filing	95 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$3.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$83.9M	2025-12-31	2026-03-10	10-K	26-100135
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$76.8M	2025-12-31	2026-03-10	10-K	26-100135
3	assets	us-gaap:Assets	$130.9M	2025-12-31	2026-03-10	10-K	26-100135
4	assets	us-gaap:Assets	$209.6M	2024-12-31	2026-03-10	10-K	26-100135
5	current assets	us-gaap:AssetsCurrent	$112.7M	2025-12-31	2026-03-10	10-K	26-100135
6	current liabilities	us-gaap:LiabilitiesCurrent	$13.1M	2025-12-31	2026-03-10	10-K	26-100135
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$330.5M	2025-12-31	2026-03-10	10-K	26-100135
8	operating income	us-gaap:OperatingIncomeLoss	-$89.8M	2025-12-31	2026-03-10	10-K	26-100135
9	book equity	us-gaap:StockholdersEquity	$110.0M	2025-12-31	2026-03-10	10-K	26-100135
10	liabilities	us-gaap:Liabilities	$21.0M	2025-12-31	2026-03-10	10-K	26-100135
11	revenue	us-gaap:Revenues	$0	2025-12-31	2026-03-10	10-K	26-100135
12	revenue	us-gaap:Revenues	$251,000	2024-12-31	2026-03-10	10-K	26-100135
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$642,000	2024-12-31	2026-03-10	10-K	26-100135
14	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$2.4M	2024-12-31	2026-03-10	10-K	26-100135
15	operating income	us-gaap:OperatingIncomeLoss	-$67.3M	2024-12-31	2026-03-10	10-K	26-100135
16	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$65.4M	2024-12-31	2025-03-24	10-K	25-043837
17	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2024-12-31	2026-03-10	10-K	26-100135
18	current assets	us-gaap:AssetsCurrent	$188.6M	2024-12-31	2026-03-10	10-K	26-100135
19	current liabilities	us-gaap:LiabilitiesCurrent	$12.3M	2024-12-31	2026-03-10	10-K	26-100135
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,716,672	2026-02-27	2026-04-30	10-K/A	26-197115
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,363,119	2025-03-19	2025-03-24	10-K	25-043837

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.